

# Tarek M Meniawy

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3093226/tarek-m-meniawy-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36  
papers

907  
citations

16  
h-index

30  
g-index

42  
ext. papers

1,245  
ext. citations

4.2  
avg, IF

3.89  
L-index

#	Paper	IF	Citations
36	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , <b>2015</b> , 6, 42008-18	3.3	238
35	Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. <i>Thorax</i> , <b>2014</b> , 69, 895-902	7.3	104
34	A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 573-82	8.9	80
33	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. <i>BMC Cancer</i> , <b>2018</b> , 18, 726	4.8	50
32	Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. <i>Cancer Letters</i> , <b>2020</b> , 468, 59-71	9.9	49
31	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 441-448	4.9	39
30	Sensitive droplet digital PCR method for detection of promoter mutations in cell free DNA from patients with metastatic melanoma. <i>Oncotarget</i> , <b>2017</b> , 8, 78890-78900	3.3	39
29	Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. <i>Oncotarget</i> , <b>2017</b> , 8, 67355-67368	3.3	34
28	Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5501-5501	2.2	32
27	PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. <i>Oncologist</i> , <b>2020</b> , 25, e520-e527	5.7	29
26	Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. <i>Molecular Oncology</i> , <b>2019</b> , 13, 171-184	7.9	27
25	Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1059-1067	8.7	23
24	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. <i>Lung Cancer</i> , <b>2016</b> , 93, 9-16	5.9	23
23	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , <b>2020</b> , 33, 358-365	4.5	21
22	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5926-5933	12.9	21
21	Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1472-1478	12.9	21
20	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3013-3013	3.2	15

19	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. <i>Oncotarget</i> , <b>2019</b> , 10, 113-122	3.3	13
18	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial <b>2021</b> , 9,		13
17	Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2102067	2.2	9
16	A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e17049-e17049	2.2	5
15	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond Mutant Detection. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
14	Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2551-2551	2.2	2
13	A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3066-3066	2.2	2
12	AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2583-2583	2.2	2
11	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	2
10	Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up. <i>International journal of gynecology and obstetrics</i> , <b>2021</b> , 134, 1036-1041	3.5	2
9	Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS3113-TPS3113	2.2	1
8	Detection of splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. <i>Oncotarget</i> , <b>2020</b> , 11, 4016-4027	3.3	1
7	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. <i>Scientific Reports</i> , <b>2021</b> , 11, 15312	4.9	1
6	Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients.. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
5	Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of SmmunomodulatorySenterocolitis. <i>Pathology</i> , <b>2018</b> , 50, 466-469	1.6	0
4	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. <i>Journal of Gynecologic Oncology</i> , <b>2021</b> , 32, e95	4	0
3	Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5584-5584	2.2	0
2	Patient human leukocyte antigen (HLA) genotype may predict response to anti-programmed death receptor 1 (anti-PD1) in advanced melanoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e21512-e21512	2.2	

- 1 A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. *Expert Review of Anticancer Therapy*, **2021**, 21, 465-474

3.5